What happened
At the American Diabetes Association meeting in New Orleans, Novo Nordisk presented the first full results from its REIMAGINE trials of CagriSema, a single injection that combines two hormones: semaglutide (the active ingredient in Ozempic and Wegovy) and a newer one called cagrilintide.
The idea is simple: two appetite signals working together should beat one. In people with type 2 diabetes, the highest dose produced an average of about 14.2% weight loss, compared with roughly 10.2% for semaglutide alone and 1.5% for placebo. It also lowered blood sugar substantially.
Why the cool reception
Those are genuinely strong numbers. But the field has a new yardstick. Eli Lilly's retatrutide has posted weight-loss figures closer to 30%, and against that backdrop, analysts described CagriSema's results as solid rather than spectacular. One Novo executive admitted "the jury is still out."
This is the real story of GLP-1s in 2026: the bar keeps rising. A result that would have been a breakthrough three years ago is now measured against an even bigger one.
What it means for you
Nothing changes for you today. CagriSema is not yet approved, and the medicines you can be prescribed now still work very well when used properly.
What is worth holding onto is this: whichever of these drugs you end up on, the part that protects your body, enough protein and some resistance training, is the same. The drug decides how much weight you lose. Those habits decide how much of it is fat and not muscle. More on that in our piece on why muscle is the number that matters.
